In Week of Mar 28, 2026, Ind-Swift Laboratories Ltd (Pharma - API) is outperforming Nifty 500 with +62.6% relative strength. Fundamentals: Average. On a 10-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Feb 22, 2026
What: ₹200-220 Cr incremental revenue expected from FY27
Impact: +₹210 Cr revenue
“Investor presentation: 'Viatris commercialization in FY27, expected to bring ₹200-220 Cr in incremental revenue'”
What: CDMO revenue expected to triple over four years
Impact: +₹350 Cr revenue
“Investor presentation: 'Key strategic growth triggers include greenfield expansion in UAE, Uzbekistan, and West Africa'”
What: EBITDA margins projected to expand by 250-300 BPS
“Investor presentation: 'EBITDA margins are projected to expand by 250-300 BPS'”
Earnings deceleration risks from management commentary
Trigger: Greenfield facility delays
Impact: -150 bps margin impact
Management view: Not specifically addressed in available materials
Monitor: Greenfield facility commissioning timelines
Trigger: Intensifying competition in export markets
Impact: -100 bps margin impact
Management view: Not specifically addressed in available materials
Monitor: Quarterly margin performance vs guidance
Key quotes from recent conference calls
“Completed ₹1,650 Cr divestment of the API & CRAMS business to Synthimed Labs, making Ind-Swift Laboratories a Net Debt Free entity — Management”
“Stable revenue for Q3 FY26, with a 6.60% increase in Operating EBITDA and a 48 BPS expansion in Operating EBITDA margin, driven by reduced raw material and employee benefit expenses — Management”
“CDMO revenue is expected to triple over four years — Management”
“Projects a topline CAGR of 20-25%, scaling from ₹550 Cr to ₹1,200+ Cr by FY29 — Management”
Forward-looking targets from management for FY26-FY29
Revenue Growth Target
20%
Implied PAT Growth
25%
OPM Guidance
8.45%
Key Milestones
• Viatris commercialization in FY27
• Greenfield expansion in UAE/Uzbekistan/West Africa
• EBITDA margin expansion by 250-300 BPS
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +17% | -19% | Inflection Up |
| PAT (Net Profit) | +274% | +80% | Inflection Up |
| OPM | 2.8% | +792 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Ind-Swift Laboratories Ltd's latest quarterly results (Dec 2025) show
Ind-Swift Laboratories Ltd's profit is growing with an turning around (inflection up) trend.
Ind-Swift Laboratories Ltd's revenue growth trend is turning around (inflection up).
Ind-Swift Laboratories Ltd's operating margin is volatile.
Ind-Swift Laboratories Ltd's long-term compounding rates
Ind-Swift Laboratories Ltd's earnings growth is turning around (inflection up) with improving on a sequential basis.
Ind-Swift Laboratories Ltd's trailing twelve month (TTM) performance
Ind-Swift Laboratories Ltd appears significantly undervalued based on our fair value analysis.
Ind-Swift Laboratories Ltd's current PE ratio is 23.8x.
Ind-Swift Laboratories Ltd's current PE is 23.8x.
Ind-Swift Laboratories Ltd's price-to-book ratio is 0.9x.
Ind-Swift Laboratories Ltd is rated Average with a fundamental score of 55.93/100. This score is calculated from objective financial metrics
Ind-Swift Laboratories Ltd has a debt-to-equity ratio of N/A.
Ind-Swift Laboratories Ltd's return ratios over recent years
Ind-Swift Laboratories Ltd's operating cash flow is negative (FY2025).
Ind-Swift Laboratories Ltd currently does not pay a significant dividend (yield 0.00%).
Ind-Swift Laboratories Ltd's shareholding pattern (Feb 2026)
Ind-Swift Laboratories Ltd's promoter holding has increased recently.
Ind-Swift Laboratories Ltd has been outperforming Nifty 500 for 10 consecutive weeks, indicating consistent outperformance.
Ind-Swift Laboratories Ltd is an established outperformer with 10 weeks of consecutive Nifty 500 outperformance.
Ind-Swift Laboratories Ltd has 3 key growth catalysts identified from recent earnings analysis
Ind-Swift Laboratories Ltd has 2 key risks worth monitoring
In Q3 FY26, Ind-Swift Laboratories Ltd's management highlighted
Ind-Swift Laboratories Ltd's management has provided the following forward guidance for FY26-FY29
Based on quantitative research signals, here is why Ind-Swift Laboratories Ltd may be worth studying
Ind-Swift Laboratories Ltd investment thesis summary:
Ind-Swift Laboratories Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
